Clinical studies show that CLENZIderm M.D.™ Normal to Oily System significantly reduces follicular P. acnes bacteria compared to a benzoyl peroxide/clindamycin combination. Reduction in follicular P. acnes was apparent three hours after the first application and sustained improvement through eight hours.

	CLENZIDERM M.D. NORMAL TO OILY SYSTEM VS. BENZOYL PEROXIDE/CLINDAMYCIN COMBINATION Reduction in inflammatory lesions Study 009B-CLENZIderm M.D. BID (N = 34)
	CLENZIDERM M.D. NORMAL TO OILY SYSTEM VS. BENZOYL PEROXIDE/CLINDAMYCIN COMBINATION Reduction in non-inflammatory lesions Study 009B-CLENZIderm M.D. BID (N = 34) * Postered at the 2007 Annual American Academy of Dermatology meeting. Click here to view the full study.

In a second clinical study, after three weeks of use, patients using CLENZIderm M.D. Normal to Oily System once daily achieved:*

• 62% reduction in sore red acne
• 47% reduction in blackheads and whiteheads

	REDUCTION IN INFLAMMATORY LESIONS WITH USE OF THE CLENZIDERM M.D. NORMAL TO OILY SYSTEM Study 013-CLENZIderm M.D. QD (N = 41)
	REDUCTION IN NON-INFLAMMATORY LESIONS WITH USE OF THE CLENZIDERM M.D. NORMAL TO OILY SYSTEM Study 013-CLENZIderm M.D. QD (N = 41) * Postered at the 2007 Winter Clinical Dermatology Conference. Click here to view the full study.

CLENZIderm M.D.™ for Normal to Dry System is clinically proven to provide fast clearance of inflammatory and non-inflammatory acne lesions while minimizing dryness and maximizing patient comfort.

In a recent clinical study, the following results were reported after 2 weeks of once-daily application:

• 50% reduction in inflammatory lesions
• 29% reduction in non-inflammatory lesions

CLENZIderm M.D. for Normal to Dry Skin is clinically proven to provide less drying and better overall comfort than the leading prescription topical benzoyl/clindamycin combination in an optimized emollient vehicle.